UPDATE 1-Regeneron-Sanofi food allergy drug succeeds mid-stage study

Oct 16 (Reuters) - Regeneron Pharmaceuticals Inc and Sanofi SA said on Monday their drug to treat infection in the esophagus, mainly caused by food allergies, met the main goal of a mid-stage study.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.